The purpose of this study is to assess platelet dependent thrombogenicity in patients after acute coronary syndrome using an ex vivo arterial injury model.
Abnormal platelet activity seen in patients with Type2 Diabetes Mellitus (T2DM) may be an important contributor to their enhanced cardiovascular risk and higher rates of cardiovascular events following acute coronary syndrome, despite dual antiplatelet therapy with aspirin and clopidogrel. We have earlier demonstrated high thrombogenicity in individuals with T2DM and CAD in the absence of acute ischaemic events, despite therapeutic doses of aspirin.We hypothesise that patients with T2DM will have increased thrombogenicity after acute coronary syndrome despite optimal secondary prevention medication.Measuring ex vivo thrombus area using an arterial injury model simulates plaque rupture and reflects the summative effect of all haemostatic abnormalities. The thrombus area of patients with ACS and T2DM will be compared to the controls without T2DM.
Study Type
OBSERVATIONAL
Enrollment
90
Royal Victoria Hospital, Newcastle upon Tyne Hospitals NHS Trust
Newcastle upon Tyne, Tyne and Wear, United Kingdom
Thrombus area
Time frame: Within 10 days after acute coronary syndrome
Factors affecting thrombus area
Time frame: Within ten days after acute coronary syndrome
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.